13 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Gainers

• Diffusion Pharmaceuticals, Inc. DFFN stock moved upwards by 41.0% to $0.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.9 million.
• Heat Biologics, Inc. HTBX stock surged 15.1% to $0.61. The market cap stands at $18.0 million.
• Myovant Sciences, Inc. MYOV shares surged 13.0% to $14.70. The market cap stands at $489.3 million. The most recent rating by Goldman Sachs, on August 28, is at Buy, with a price target of $20.00.
• Canopy Growth, Inc. CGC stock rose 6.3% to $16.28. The market value of their outstanding shares is at $9.1 billion. According to the most recent rating by Bank of America, on November 20, the current rating is at Buy.
• Endo International, Inc. ENDP stock surged 5.6% to $4.70. The market cap seems to be at $1.0 billion.
• Aurora Cannabis, Inc. ACB shares moved upwards by 3.2% to $2.41. The market value of their outstanding shares is at $4.8 billion. The most recent rating by Piper Jaffray, on October 22, is at Neutral, with a price target of $4.00.
• Cronos Group, Inc. CRON stock increased by 1.5% to $6.80. The market cap seems to be at $3.6 billion. The most recent rating by Bank of America, on November 13, is at Buy, with a price target of $15.00.
• OrganiGram Holdings, Inc. OGI stock rose 1.3% to $2.35. The market cap seems to be at $710.5 million.

Losers

• Phio Pharmaceuticals, Inc. PHIO shares decreased by 15.1% to $0.11 during Wednesday's pre-market session. The market cap seems to be at $5.7 million.
• Amarin Corp, Inc. AMRN stock plummeted 6.2% to $21.33. The market value of their outstanding shares is at $5.8 billion. The most recent rating by Oppenheimer, on November 20, is at Underperform, with a price target of $7.00.
• Advaxis, Inc. ADXS stock declined 5.3% to $0.37. The market cap seems to be at $6.1 million.
• Fresenius Medical Care, Inc. FMS shares plummeted 1.2% to $36.66. According to the most recent rating by Redburn, on October 23, the current rating is at Neutral.
• Novo Nordisk, Inc. NVO stock plummeted 1.0% to $56.45. According to the most recent rating by Barclays, on November 18, the current rating is at Overweight.